[go: up one dir, main page]

WO2009127612A1 - Nouveaux dérivés de pyrazole - Google Patents

Nouveaux dérivés de pyrazole Download PDF

Info

Publication number
WO2009127612A1
WO2009127612A1 PCT/EP2009/054386 EP2009054386W WO2009127612A1 WO 2009127612 A1 WO2009127612 A1 WO 2009127612A1 EP 2009054386 W EP2009054386 W EP 2009054386W WO 2009127612 A1 WO2009127612 A1 WO 2009127612A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
formula
chloro
phenyl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2009/054386
Other languages
English (en)
Inventor
Raphael Dumeunier
Clemens Lamberth
Stephan Trah
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syngenta Participations AG
Original Assignee
Syngenta Participations AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syngenta Participations AG filed Critical Syngenta Participations AG
Priority to EP09732982A priority Critical patent/EP2274285A1/fr
Publication of WO2009127612A1 publication Critical patent/WO2009127612A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/16—Halogen atoms or nitro radicals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/48—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with two nitrogen atoms as the only ring hetero atoms
    • A01N43/56—1,2-Diazoles; Hydrogenated 1,2-diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the present invention relates to novel pyrazole derivatives as active ingredients which have microbiocidal activity, in particular fungicidal activity.
  • the invention also relates to preparation of these active ingredients, to novel heterocyclic derivatives used as intermediates in the preparation of these active ingredients, to preparation of these novel intermediates, to agrochemical compositions which comprise at least one of the novel active ingredients, to preparation of these compositions and to use of the active ingredients or compositions in agriculture or horticulture for controlling or preventing infestation of plants, harvested food crops, seeds or non-living materials by phytopathogenic microorganisms, preferably fungi.
  • the present invention also relates to the use of these novel pyrazole derivatives as plant growth regulators (PGRs).
  • PGRs plant growth regulators
  • compositions comprising the novel pyrazole derivatives that improve plants, a process which is commonly and hereinafter referred to as "plant health”.
  • the present invention further relates to the use of these novel pyrazole derivatives in the treatment of cancer and to pharmaceutical compositions comprising at least one of these compounds as active component.
  • the present invention provides a compound of formula I:
  • R 1 is Ci-C 4 alkyl or C r C 4 haloalkyl
  • R 2 is an optionally substituted aryl or heteroaryl
  • R 3 is halogen
  • R 4 is hydrogen, halogen, Ci-C 4 alkyl, CrC 4 haloalkyl, cyano or OR 6 ;
  • R 5 is hydrogen, halogen, Ci-C 4 alkyl, Ci-C 4 haloalkyl, cyano or OR 6 ;
  • R 6 is hydrogen, CrC 6 alkyl, C 3 -C 7 cycloalkyl, C 3 -Ci 0 alkylcycloalkyl, CrC 6 haloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 haloalkenyl, C 3 -C 7 cycloalkenyl, C 2 -C 6 alkynyl, C 2 -C 6 haloalkynyl, C 2 -C 6 alkyloxyalkyl;
  • R 7 is halogen or OR 6 ;
  • X is N or C-R 4 ; or an agrochemically usable salt form thereof.
  • aryl includes aromatic hydrocarbon rings like phenyl, naphthyl, anthracenyl, phenanthrenyl and biphenyl, with phenyl being preferred.
  • Heteroaryl stands for aromatic ring systems comprising mono-, bi- or tricyclic systems wherein at least one oxygen, nitrogen or sulfur atom is present as a ring member.
  • Examples are furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, tetrazinyl, indolyl, benzothiophenyl, benzofuranyl, benzimidazolyl, indazolyl, benzotriazolyl, benzothiazolyl, benzoxazolyl, quinolyl, isoquinolyl, phthalazinyl, quinoxalinyl,
  • fused ring, carbocyclic ring, heterocyclic ring, aryl group and heteroaryl group may be optionally substituted. This means that they may carry one or more identical or different substituents. Normally not more than three substituents are present at the same time.
  • substituents are: halogen, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, alkenyl, haloalkenyl, cycloalkenyl, alkynyl, haloalkynyl, alkyloxy, haloalkyloxy, cycloalkoxy, alkenyloxy, haloalkenyloxy, alkynyloxy, haloalkenyloxy, alkylthio, haloalkylthio, cycloalkylthio, alkenylthio, alkynylthio, alkylcarbonyl, haloalkylcarbonyl, cycloalkylcarbonyl, alkenylcarbonyl, alkynylcarbonyl, alkoxyalkyl, cyano, nitro, hydroxy, mercapto, amino, alkylamino, dialkylamino.
  • Typical examples for optionally substituted aryl include 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2-chlorophenyl, 3-chlorophenyl, 4- chlorophenyl, 3-bromophenyl, 4-bromophenyl, m-tolyl, p-tolyl, 3-trifluoromethylphenyl, 4- trifluoromethylphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 3-trifluoromethoxyphenyl, 4- trifluoromethoxyphenyl, 3-cyanophenyl, 4-cyanophenyl, 2,4-difluorophenyl, 2,5- difluorophenyl, 2,6-difluorophenyl, 3,4-difluorophenyl, 2,4-dichlorophenyl, 2,5- dichlorophenyl, 2,6-dichlorophenyl, 3,4-dichlorophenyl, 3,4-
  • Typical examples for optionally substituted heteroaryl include 6-chloropyridin-2-yl, 6-fluoropyridin-2-yl, 6-methoxypyridin-2-yl, 6-methylpyridin-2-yl, 6-chloropyridin-3-yl, 6-f I uoropy rid i n-3-y 1 , 6-methoxypyridin-3-yl, 6-methylpyridin-3-yl, 2- chloropyridin-4-yl, 2-fluoropyridin-4-yl, 2-methoxypyridin-4-yl, 2-methylpyridin-4-yl, 3,5- dichloropyridin-2-yl, 3,5-difluoropyridin-2-yl, 3-chloro-5-fluoropyridin-2-yl, 3-chloro-5- methylpyridin-2-yl, 3-chloro-5-trifluoromethylpyridin-2-yl, 3-chloro-5-methoxypyridin-2-yl, 3-
  • halogen is fluorine, chlorine, bromine or iodine.
  • alkyl, alkenyl and alkynyl moieties can be in the form of straight or branched chains, and the alkenyl moieties, where appropriate, can be of either the (EJ- or (Z)-configuration. Examples are vinyl, allyl and propargyl. Alkenyl and alkynyl - A -
  • moieties can contain one or more double and/or triple bonds in any combination. It is understood, that allenyl and alkylinylalkenyl are included in these terms.
  • C 2 -C 6 alkyloxyalkyl for example, means that the sum of the carbon atoms of the two alkyl parts is between 2 and 6 carbon atoms.
  • C 3 -C 8 dialkylaminoalkyl or C 4 -Ci 0 heterocyclylalkyl as a matter of example, it also applies to C 3 -C 8 dialkylaminoalkyl or C 4 -Ci 0 heterocyclylalkyl.
  • Alkyl on its own or as part of another substituent is, depending upon the number of carbon atoms mentioned, for example, methyl, ethyl, propyl, butyl, pentyl, hexyl and the isomers thereof, for example, isopropyl, isobutyl, sec-butyl, tert-butyl, isopentyl or tert- pentyl.
  • a haloalkyl group may contain one or more identical or different halogen atoms and, for example, may stand for CH 2 CI, CHCI 2 , CCI 3 , CH 2 F, CHF 2 , CF 3 , CF 3 CH 2 , CH 3 CF 2 , CF 3 CF 2 Or CCI 3 CCI 2 .
  • Cycloalkyl on its own or as part of another substituent is, depending upon the number of carbon atoms mentioned, for example, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.
  • Alkenyl on its own or as part of another substituent is, depending upon the number of carbon atoms mentioned, for example, ethenyl, allyl, 1-propenyl, buten-2-yl, buten-3-yl, penten-1-yl, penten-3-yl, hexen-1-yl or 4-methyl-3-pentenyl.
  • Alkynyl on its own or as part of another substituent is, depending upon the number of carbon atoms mentioned, for example, ethynyl, propyn-1-yl, propyn-2-yl, butyn-1-yl, butyn- 2-yl, 1-methyl-2-butynyl, hexyn-1-yl or 1 -ethyl-2-butynyl.
  • the presence of one or more possible asymmetric carbon atoms in a compound of formula I means that the compounds may occur in optically isomeric, that means enantiomeric or diastereomeric forms.
  • optically isomeric that means enantiomeric or diastereomeric forms.
  • geometric isomerism that means cis-trans or [E)-(Z) isomerism may also occur.
  • atropisomers may occur as a result of restricted rotation about a single bond.
  • Formula I is intended to include all those possible isomeric forms and mixtures thereof.
  • the present invention intends to include all those possible isomeric forms and mixtures thereof for a compound of formula I.
  • the compounds of formula I according to the invention are in free form or in an agronomically usable salt form.
  • compounds of formula I according to the invention have R 1 which is Ci-C 3 alkyl or d-C 3 haloalkyl.
  • compounds of formula I according to the invention have R 2 which is an optionally substituted phenyl, naphtyl, pyridinyl or quinolyl.
  • compounds of formula I according to the invention have R 3 which is chloro, fluoro or bromo.
  • compounds of formula I according to the invention have R 4 which is hydrogen, chloro, fluoro, C- ⁇ -C 3 alkyl or OR 6 .
  • compounds of formula I according to the invention have R 5 which is hydrogen, chloro, fluoro, Ci-C 3 alkyl, cyano or OR 6 .
  • compounds of formula I according to the invention have R 6 which is CrC 6 alkyl, C 3 -C 7 cycloalkyl, CrC 6 haloalkyl, C 2 -C 6 alkenyl or C 2 -C 6 alkynyl.
  • compounds of formula I according to the invention have R 7 which is chloro, fluoro, bromo or OR 6 .
  • R 7 which is chloro, fluoro, bromo or OR 6 .
  • Preferred subgroups of compounds of formula I according to the invention are those wherein R 1 is CrC 2 alkyl;
  • R 2 is 3-fluorophenyl, 4-fluorophenyl, 3-chlorophenyl, 4-chlorophenyl, 3-bromophenyl, 4- bromophenyl, m-tolyl, p-tolyl, 3-methoxyphenyl, 4-methoxyphenyl, 3-cyanophenyl, 4- cyanophenyl, 3,4-difluorophenyl, 3,4-dichlorophenyl, 3-chloro-4-fluorophenyl, 4-chloro-3- fluorophenyl, naphth-2-yl, pyridin-3-yl, 6-chloropyridin-3-yl, 6-fluoropyridin-3-yl, 6- methoxypyridin-3-yl, 6-methylpyridin-3-yl, quinolin-2-yl, quinolin-3-yl, 4-methoxyquinolin-2-yl or 4-methylquinolin-2-yl; R 3 is chloro or fluor
  • R 4 is hydrogen, chloro or fluoro
  • R 5 is hydrogen, chloro, fluoro or OR 6 ;
  • R 6 is CrC 3 alkyl
  • R 7 is chloro, fluoro, OR 6 ; and X is N or C-R 4 .
  • More preferred subgroups of compounds of formula I according to the invention are those wherein R 1 is methyl; R 2 is 4-chlorophenyl or 4-methoxyphenyl; R 3 is chloro;
  • R 4 is hydrogen or fluoro;
  • R 5 is fluoro or OR 6 ;
  • R 6 is methyl;
  • R 7 is chloro or fluoro;
  • Preferred individual compounds are:
  • the compounds of formula 1.1 wherein R 2 , R 5 , R 7 and X are as defined for compound of formula I, and R 1 is CrC 4 alkyl or Ci-C 4 haloalkyl, can be obtained by reaction of a compound of formula II, wherein R 2 , R 5 , R 7 and X are as defined for compound of formula I, and R 1 is CrC 4 alkyl or Ci-C 4 haloalkyl, in classical Sandmeyer reaction conditions.
  • the compounds of formula 1.2 wherein R 2 and R 6 are as defined for compound of formula I, and R 1 is Ci-C 4 alkyl, can be obtained by reaction of a compound of formula 1.3, wherein R 2 is as defined for compound of formula I, and R 1 is CrC 4 alkyl, with a reagent of formula NaOR 6 , wherein R 6 is as defined for compound of formula I.
  • the compounds of formula II wherein R 2 , R 5 , R 7 and X are as defined for compound of formula I, and R 1 is CrC 4 alkyl, can be obtained by transformation of a compound of formula III, wherein R 2 , R 5 , R 7 and X are as defined for compound of formula I, and R 1 is Cr C 4 alkyl, with an oxidant such as manganese dioxide.
  • the compounds of formula III wherein R 2 , R 5 , R 7 and X are as defined for compound of formula I, and R 1 is Ci-C 4 alkyl or Ci-C 4 haloalkyl, can be obtained by transformation of a compound of formula IV, wherein R 2 , R 5 , R 7 and X are as defined for compound of formula I, with a reagent of formula V, wherein R 1 is Ci-C 4 alkyl or Ci-C 4 haloalkyl.
  • the compounds of formula IV wherein R 2 , R 5 , R 7 and X are as defined for compound of formula I, can be obtained by reaction of a compound of formula Vl, wherein R 5 , R 7 and X are as defined for compound of formula I, with an aldehyde of formula VII wherein R 2 is as defined for compound of formula I, in the presence of a base such as potassium carbonate.
  • the compounds of formula 1.1 wherein R 2 , R 5 , R 7 and X are as defined for compound of formula I, and R 1 is CrC 4 alkyl or Ci-C 4 haloalkyl, can be alternatively be obtained by reaction of a compound of formula VIII, wherein R 2 , R 5 , R 7 and X are as defined for compound of formula I, with a reagent of formula R 1 HaI, wherein R 1 is as defined for compound of formula I, and Hal is halogene, preferentially iodine, in the presence of a base.
  • the compounds of formula VIII wherein R 2 , R 5 , R 7 and X are as defined for compound of formula I, can be obtained by reduction of a compound of formula IX, wherein R 2 , R 5 , R 7 and X are as defined for compound of formula I, in the presence of cyclohexene and palladium hydroxide.
  • the compounds of formula IX wherein R 2 , R 5 , R 7 and X are as defined for compound of formula I, can be obtained by reaction of a compound of formula X, wherein R 2 , R 5 , R 7 and X are as defined for compound of formula I, with benzylhydrazine.
  • the compounds of formula X.1 wherein R 5 , R 7 and X are as defined for compound of formula I, can be obtained by a Friedel-Craft reaction of a compound of formula Xl, wherein R 5 , R 7 and X are as defined for compound of formula I, with anisole in the presence of aluminum trichloride.
  • the compounds of formula Xl wherein R , R and X are as defined for compound of formula I, can be obtained by a reaction of a compound of formula XII, wherein R 5 , R 7 and X are as defined for compound of formula I, with thionyl choride.
  • the compounds of formula XII, wherein R 5 , R 7 and X are as defined for compound of formula I can be obtained by a reaction of a compound of formula XIII, wherein R 5 , R 7 and X are as defined for compound of formula I, with potassium hydroxide in methanol.
  • the compounds of formula XIII, wherein R 5 , R 7 and X are as defined for compound of formula I, can be obtained by a reaction of a compound of formula XIV, wherein R 5 , R 7 and X are as defined for compound of formula I, with carbon tetrachloride in the presence of triphenylphosphine.
  • the compound of formula XIV, wherein R 5 and R 7 are fluoro, and X is C-F can be obtained by a reaction of a compound of formula XV, wherein R 5 and R 7 are fluoro, and X is C-F, with isopropyl magnesium chloride, followed by reaction with EtO 2 CCO 2 Et.
  • the compounds of formula I can be used in the agricultural sector and related fields of use as active ingredients for controlling plant pests or on non-living materials for control of spoilage microorganisms or organisms potentially harmfull to man.
  • the novel compounds are distinguished by excellent activity at low rates of application, by being well tolerated by plants and by being environmentally safe. They have very useful curative, preventive and systemic properties and are used for protecting numerous cultivated plants.
  • the compounds of formula I can be used to inhibit or destroy the pests that occur on plants or parts of plants (fruit, blossoms, leaves, stems, tubers, roots) of different crops of useful plants, while at the same time protecting also those parts of the plants that grow later e.g. from phytopathogenic microorganisms.
  • compositions comprising a compound of formula I before planting: seed, for example, can be dressed before being sown.
  • the active ingredients according to the invention can also be applied to grains (coating), either by impregnating the seeds in a liquid formulation or by coating them with a solid formulation.
  • the composition can also be applied to the planting site when the propagation material is being planted, for example, to the seed furrow during sowing. The invention relates also to such methods of treating plant propagation material and to the plant propagation material so treated.
  • the compounds according to present invention can be used for controlling fungi in related areas, for example in the protection of technical materials, including wood and wood related technical products, in food storage, in hygiene management.
  • the invention could be used to protect non-living materials from fungal attack, e.g. lumber, wall boards and paint.
  • the compounds of formula I are, for example, effective against the phytopathogenic fungi of the following classes: Fungi imperfecti (e.g. Alternaria spp.), Basidiomycetes (e.g. Corticium spp., Ceratobasidium spp., Waitea spp., Thanatephorus spp., Rhizoctonia spp., Hemileia spp., Puccinia spp., Phakopsora spp., Ustilago spp., Tilletia spp.), Ascomycetes (e.g.
  • Venturia spp. Blumeria spp., Erysiphe spp., Podosphaera spp., Uncinula spp., Monilinia spp., Sclerotinia spp., Colletotrichum spp., Glomerella spp., Fusarium spp., Gibberella spp., Monographella spp., Phaeosphaeria spp., Mycosphaerella spp., Cercospora spp., Pyrenophora spp., Rhynchosporium spp., Magnaporthe spp., Gaeumannomyces spp., Oculimacula spp., Ramularia spp., Botryotinia spp.) and
  • Oomycetes e.g. Phytophthora spp., Pythium spp., Plasmopara spp., Peronospora spp., Pseudoperonospora spp. Bremia spp.
  • Outstanding activity is observed against powdery mildews (e.g. Erysiphe necato ⁇ and leaf spots (e.g. Mycosphaerella spp.).
  • the novel compounds of formula I are effective against phytopathogenic gram negative and gram positive bacteria (e.g. Xanthomonas spp, Pseudomonas spp, Erwinia amylovora, Ralstonia spp.) and viruses (e.g. tobacco mosaic virus).
  • target crops to be protected typically comprise the following species of plants: cereal (wheat, barley, rye, oat, rice, maize, sorghum and related species); beet (sugar beet and fodder beet); pomes, drupes and soft fruit (apples, pears, plums, peaches, almonds, cherries, strawberries, raspberries and blackberries); leguminous plants (beans, lentils, peas, soybeans); oil plants (rape, mustard, poppy, olives, sunflowers, coconut, castor oil plants, cocoa beans, groundnuts); cucumber plants (pumpkins, cucumbers, melons); fibre plants (cotton, flax, hemp, jute); citrus fruit (oranges, lemons, grapefruit, mandarins); vegetables (spinach, lettuce, asparagus, cabbages, carrots, onions, tomatoes, potatoes, paprika); lauraceae (avocado, cinnamomum, camphor) or plants such as tobacco
  • the useful plants and / or target crops in accordance with the invention include conventional as well as genetically enhanced or engineered varieties such as, for example, insect resistant (e.g. Bt. and VIP varieties) as well as disease resistant, herbicide tolerant (e.g. glyphosate- and glufosinate-resistant maize varieties commercially available under the trade names RoundupReady® and LibertyLink®) and nematode tolerant varieties.
  • suitable genetically enhanced or engineered crop varieties include the Stoneville 5599BR cotton and Stoneville 4892BR cotton varieties.
  • useful plants and/or “target crops” is to be understood as including also useful plants that have been rendered tolerant to herbicides like bromoxynil or classes of herbicides (such as, for example, HPPD inhibitors, ALS inhibitors, for example primisulfuron, prosulfuron and trifloxysulfuron, EPSPS (5-enol-pyrovyl-shikimate-3- phosphate-synthase) inhibitors, GS (glutamine synthetase) inhibitors or PPO (protoporphyrinogen-oxidase) inhibitors) as a result of conventional methods of breeding or genetic engineering.
  • herbicides like bromoxynil or classes of herbicides
  • EPSPS (5-enol-pyrovyl-shikimate-3- phosphate-synthase) inhibitors
  • GS glutamine synthetase
  • PPO protoporphyrinogen-oxidase
  • Clearfield® summer rape (Canola).
  • crops that have been rendered tolerant to herbicides or classes of herbicides by genetic engineering methods include glyphosate- and glufosinate-resistant maize varieties commercially available under the trade names RoundupReady® , Herculex I® and LibertyLink®.
  • useful plants and/or target crops is to be understood as including also useful plants which have been so transformed by the use of recombinant DNA techniques that they are capable of synthesising one or more selectively acting toxins, such as are known, for example, from toxin-producing bacteria, especially those of the genus Bacillus.
  • useful plants and/or target crops is to be understood as including also useful plants which have been so transformed by the use of recombinant DNA techniques that they are capable of synthesising antipathogenic substances having a selective action, such as, for example, the so-called "pathogenesis-related proteins” (PRPs, see e.g. EP-A-O 392 225).
  • PRPs pathogenesis-related proteins
  • antipathogenic substances examples include antipathogenic substances, transgenic plants capable of synthesising such antipathogenic substances, for example, from EP-A-O 392 225, WO 95/33818, and EP-A-O 353 191.
  • the methods of producing such transgenic plants are generally known to the person skilled in the art and are described, for example, in the publications mentioned above.
  • locus of a useful plant as used herein is intended to embrace the place on which the useful plants are growing, where the plant propagation materials of the useful plants are sown or where the plant propagation materials of the useful plants will be placed into the soil.
  • An example for such a locus is a field, on which crop plants are growing.
  • plant propagation material is understood to denote generative parts of the plant, such as seeds, which can be used for the multiplication of the latter, and vegetative material, such as cuttings or tubers, for example potatoes. There may be mentioned for example seeds (in the strict sense), roots, fruits, tubers, bulbs, rhizomes and parts of plants. Germinated plants and young plants which are to be transplanted after germination or after emergence from the soil, may also be mentioned. These young plants may be protected before transplantation by a total or partial treatment by immersion. Preferably "plant propagation material” is understood to denote seeds.
  • the compounds of formula I are used in unmodified form or, preferably, together with the adjuvants conventionally employed in the art of formulation. To this end they are conveniently formulated in known manner to emulsifiable concentrates, coatable pastes, directly sprayable or dilutable solutions or suspensions, dilute emulsions, wettable powders, soluble powders, dusts, granulates, and also encapsulations e.g. in polymeric substances.
  • the methods of application such as spraying, atomising, dusting, scattering, coating or pouring, are chosen in accordance with the intended objectives and the prevailing circumstances.
  • the compositions may also contain further adjuvants such as stabilizers, antifoams, viscosity regulators, binders or tackifiers as well as fertilizers, micronutrient donors or other formulations for obtaining special effects.
  • Suitable carriers and adjuvants can be solid or liquid and are substances useful in formulation technology, e.g. natural or regenerated mineral substances, solvents, dispersants, wetting agents, tackifiers, thickeners, binders or fertilizers. Such carriers are for example described in WO 97/33890.
  • the compounds of formula I are normally used in the form of compositions and can be applied to the crop area or plant to be treated, simultaneously or in succession with further compounds.
  • further compounds can be e.g. fertilizers or micronutrient donors or other preparations, which influence the growth of plants. They can also be selective herbicides or non-selective herbicides as well as insecticides, fungicides, bactericides, nematicides, molluscicides or mixtures of several of these preparations, if desired together with further carriers, surfactants or application promoting adjuvants customarily employed in the art of formulation.
  • the compounds of formula I are normally used in the form of fungicidal compositions for controlling or protecting against phytopathogenic microorganisms, comprising as active ingredient at least one compound of formula I or of at least one preferred individual compound as above-defined, in free form or in agrochemically usable salt form, and at least one of the above-mentioned adjuvants.
  • Said fungicidal compositions for controlling or protecting against phytopathogenic microorganisms comprising as active ingredient at least one compound of formula I or at least one preferred individual compound as above-defined, in free form or in agrochemically usable salt form, and at least one of the above-mentioned adjuvants can be mixed with other fungicides, resulting in some cases in unexpected synergistic activities.
  • Azoles such as azaconazole, BAY 14120, bitertanol, bromuconazole, cyproconazole, difenoconazole, diniconazole, epoxiconazole, fenbuconazole, fluquinconazole, flusilazole, flutriafol, hexaconazole, imazalil, imibenconazole, ipconazole, metconazole, myclobutanil, pefurazoate, penconazole, prothioconazole, pyrifenox, prochloraz, propiconazole, simeconazole, tebuconazole, tetraconazole, triadimefon, triadimenol, triflumizole, triticonazole;
  • Azoles such as azaconazole, BAY 14120, bitertanol, bromuconazole, cyproconazole, dif
  • Pyrimidinyl carbinoles such as ancymidol, fenarimol, nuarimol;
  • 2-amino-pyrimidines such as bupirimate, dimethirimol, ethirimol
  • Morpholines such as dodemorph, fenpropidine, fenpropimorph, spiroxamine, tridemorph;
  • Anilinopyrimidines such as cyprodinil, mepanipyrim, pyrimethanil;
  • Pyrroles such as fenpiclonil, fludioxonil
  • Phenylamides such as benalaxyl, furalaxyl, metalaxyl, R-metalaxyl, ofurace, oxadixyl;
  • Benzpyrazoles such as benomyl, carbendazim, debacarb, fuberidazole, thiaben- dazole;
  • Dicarboximides such as chlozolinate, dichlozoline, iprodione, myclozoline, procymi- done, vinclozoline;
  • Carboxamides such as boscalid, carboxin, fenfuram, flutolanil, mepronil, oxycarboxin, penthiopyrad, thifluzamide; guanidines, such as guazatine, dodine, iminoctadine; Strobilurines, such as azoxystrobin, dimoxystrobin, enestroburin, fluoxastrobin, kresoxim-methyl, metominostrobin, trifloxystrobin, orysastrobin, picoxystrobin, pyraclostrobin;
  • Dithiocarbamates such as ferbam, mancozeb, maneb, metiram, propineb, thiram, zineb, ziram; N-halomethylthiotetrahydrophthalimides, such as captafol, captan, dichlofluanid, fluoromides, folpet, tolyfluanid;
  • Cu-compounds such as Bordeaux mixture, copper hydroxide, copper oxychloride, copper sulfate, cuprous oxide, mancopper, oxine-copper;
  • Nitrophenol-derivatives such as dinocap, nitrothal-isopropyl
  • Organo-phosphorus-derivatives such as edifenphos, iprobenphos, isoprothiolane, phosdiphen, pyrazophos, tolclofos-methyl
  • Triazolopyrimidine derivatives which are known and may be prepared by methods as described in WO98/46607, such as 5-chloro-7-(4-methyl-piperidin-1-yl)-6-(2,4,6-trifluoro- phenyl)- [1 ,2,4]triazolo[1 ,5-a]pyrimidine (formula T.1 );
  • Carboxamide derivatives which are known and may be prepared by methods as described in WO04/035589 and in WO06/37632, such as 3-difluoromethyl-1-methyl-1 H- pyrazole-4-carboxylic acid (9-isopropyp-1 ,2,3,4-tetrahaydro-1 ,4-methano-naphthalen-5-yl)- amide (formula U.1 ); or
  • Benzamide derivatives which are known and may be prepared by methods as described in WO 2004/016088, such as N- ⁇ -2-[3-chloro-5-(trifluoromethyl)-2-pyridinyl]ethyl ⁇ - 2-trifluoromethylbenzamide, which is also known under the name fluopyram (formula V.1 );
  • Another aspect of invention is related to the use of a compound of formula I or of a preferred individual compound as above-defined, of a composition comprising at least one compound of formula I or at least one preferred individual compound as above-defined, or of a fungicidal mixture comprising at least one compound of formula I or at least one preferred individual compound as above-defined, in admixture with other fungicides, as described above, for controlling or preventing infestation of plants, harvested food crops, seeds or non-living materials by phytopathogenic microorganisms, preferably fungal organisms.
  • a further aspect of invention is related to a method of controlling or preventing an infestation of crop plants, harvested food crops or of non-living materials by phytopathogenic or spoilage microorganisms or organisms potentially harmful to man, especially fungal organisms, which comprises the application of a compound of formula I or of a preferred individual compound as above-defined as active ingredient to the plants, to parts of the plants or to the locus thereof, to seeds or to any part of the non-living materials.
  • Controlling or preventing means reducing the infestation of crop plants or of non-living materials by phytopathogenic or spoilage microorganisms or organisms potentially harmful to man, especially fungal organisms, to such a level that an improvement is demonstrated.
  • a preferred method of controlling or preventing an infestation of crop plants by phytopathogenic microorganisms, especially fungal organisms, which comprises the application of a compound of formula I, or an agrochemical composition which contains at least one of said compounds, is foliar application.
  • the frequency of application and the rate of application will depend on the risk of infestation by the corresponding pathogen.
  • the compounds of formula I can also penetrate the plant through the roots via the soil (systemic action) by drenching the locus of the plant with a liquid formulation, or by applying the compounds in solid form to the soil, e.g. in granular form (soil application). In crops of water rice such granulates can be applied to the flooded rice field.
  • the compounds of formula I may also be applied to seeds (coating) by impregnating the seeds or tubers either with a liquid formulation of the fungicide or coating them with a solid formulation.
  • a formulation that is, a composition containing the compound of formula I] and, if desired, a solid or liquid adjuvant or monomers for encapsulating the compound of formula I, is prepared in a known manner, typically by intimately mixing and/or grinding the compound with extenders, for example solvents, solid carriers and, optionally, surface active compounds (surfactants).
  • extenders for example solvents, solid carriers and, optionally, surface active compounds (surfactants).
  • the agrochemical formulations will usually contain from 0.1 to 99% by weight, preferably from 0.1 to 95% by weight, of the compound of formula I, 99.9 to 1 % by weight, preferably 99.8 to 5% by weight, of a solid or liquid adjuvant, and from 0 to 25% by weight, preferably from 0.1 to 25% by weight, of a surfactant.
  • Advantageous rates of application are normally from 5g to 2kg of active ingredient (a.i.) per hectare (ha), preferably from 1 Og to 1 kg a.i./ha, most preferably from 2Og to 60Og a.i./ha.
  • convenient dosages are from 10mg to 1 g of active substance per kg of seeds.
  • Plant growth regulators are generally any substances or mixtures of substances intended to accelerate or retard the rate of growth or maturation, or otherwise alter the development of plants or their produce.
  • Plant growth regulators affect growth and differentiation of plants.
  • various plant growth regulators can, for example, reduce plant height, stimulate seed germination, induce flowering, darken leaf coloring, change the rate of plant growth and modify the timing and efficiency of fruiting.
  • the present invention also relates to compositions comprising the novel pyrazole derivatives of the present invention that improve plants, a process which is commonly and hereinafter referred to as "plant health”.
  • advantageous properties are improved crop characteristics including: emergence, crop yields, protein content, increased vigour, faster maturation, increased speed of seed emergence, improved nitrogen utilization efficiency, improved water use efficiency, improved oil content and /or quality, improved digestibility, faster ripening, improved flavor, improved starch content, more developed root system (improved root growth), improved stress tolerance (e.g.
  • tillering increase, increase in plant height, bigger leaf blade, less dead basal leaves, stronger tillers, greener leaf color, pigment content, photosynthetic activity, less input needed (such as fertilizers or water), less seeds needed, more productive tillers, earlier flowering, early grain maturity, less plant verse (lodging), increased shoot growth, enhanced plant vigor, increased plant stand and early and better germination.
  • Advantageous properties obtained especially from treaded seeds, are e.g. improved germination and field establishment, better vigor, more homogeneous field establishment.
  • Advantageous properties, obtained especially from foliar and/or in-furrow application are e.g. improved plant growth and plant development, better growth, more tillers, greener leafes, largers leaves, more biomass, better roots, improved stress tolerance of the plants, more grain yield, more biomass harvested, improved quality of the harvest (content of fatty acids, metabolites, oil etc), more marketable products (e.g. improved size), improved process (e.g. longer shelf-life, better extraction of compounds), improved quality of seeds (for being seeded in the following seasons for seed production); or any other advantages familiar to a person skilled in the art.
  • the present invention relates to plant-protecting active ingredients that are pyrazole compounds of formula I according to the invention, in particular the individual pyrazole compounds described in the above description as being preferred, and mixtures with increased efficacy and to a method of improving the health of plants by applying said compounds and mixtures to the plants or the locus thereof.
  • the action of the compounds of formula I goes beyond the known fungicidal action.
  • the pyrazole compounds of formula I according to the invention in particular the individual pyrazole compounds described in the above description as being preferred compounds exhibit plant health.
  • plant health comprises various sorts of improvements of plants that are not connected to the control of harmful fungi.
  • the present invention relates to a composition
  • a composition comprising at least one compound a compound of formula I or of a preferred individual compound as above- defined and / or at least one pharmaceutically acceptable salt thereof, at least one pharmaceutically acceptable carrier and / or at least one pharmaceutically acceptable diluent.
  • the present invention also relates to a compound of formula I or of a preferred individual compound as above-defined, or a pharmaceutically acceptable salt thereof for use as a medicament.
  • the present invention also relates to a compound of formula I or of a preferred individual compound as above-defined, or a pharmaceutically acceptable salt thereof for the treatment of cancer.
  • the present invention also relates to the use of a compound formula I or of a preferred individual compound as above-defined, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of cancer.
  • the present invention also relates to a method of treating cancer in a subject in need thereof, comprising administering a a compound formula I or of a preferred individual compound as above-defined to said subject in an amount effective to treat said cancer.
  • the invention further provides fungicidal or pharmaceutical compositions comprising these compounds I and/or their agriculturally or pharmaceutically acceptable salts and suitable carriers.
  • Suitable pharmaceutically acceptable carriers are described below.
  • pyrazole compounds of formula I according to the invention in particular the pyrazoles of formula I according to the invention described in the above description as being preferred, and/or their pharmaceutically acceptable salts are suitable for the treatment, inhibitor! or control of growth and/or propagation of tumor cells and the disorders associated therewith.
  • mammals and birds for example mammals and birds, in particular man, but also other mammals, in particular useful and domestic animals, such as dogs, cats, pigs, ruminants (cattle, sheep, goats, bison, etc.), horses and birds, such as chicken, turkey, ducks, geese, guineafowl and the like.
  • pyrazoles of formula I according to the invention in particular the pyrazoles of formula I according to the invention described in the above description as being preferred, and/or their pharmaceutically acceptable salts are suitable for the therapy of cancer or cancerous disorders of the following organs: breast, lung, intestine, prostate, skin (melanoma), kidney, bladder, mouth, larynx, oesophagus, stomach, ovaries, pancreas, liver and brain.
  • compositions according to the invention comprise at least optionally a suitable carrier.
  • “Pharmaceutically acceptable” means compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
  • Suitable carriers are, for example, solvents, carriers, excipients, binders and the like customarily used for pharmaceutical formulations, which are described below in an exemplary manner for individual types of administration.
  • “Pharmaceutically acceptable carrier” as used herein means a pharmaceutically- acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting the subject agent from one organ, or portion of the body, to another organ, or portion of the body.
  • a pharmaceutically- acceptable material, composition or vehicle such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting the subject agent from one organ, or portion of the body, to another organ, or portion of the body.
  • Each carrier must be “acceptable” in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient.
  • materials which can serve as pharmaceutically-acceptable carriers include: sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa butter and suppository waxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols, such as propylene glycol; polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffering agents, such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline;
  • Ringer's solution ethyl alcohol; phosphate buffer solutions; and other non-toxic compatible substances employed in pharmaceutical formulations.
  • the pyrazole compounds of formula I according to the invention in particular the individual pyrazole compounds described in the above description as being preferred (the active compound), can be administered in a customary manner, for example orally, intravenously, intramuscularly or subcutaneously.
  • the active compound can be mixed, for example, with an inert diluent or with an edible carrier; it can be embedded into a hard or soft gelatin capsule, it can be compressed to tablets or it can be mixed directly with the food/feed.
  • the active compound can be mixed with excipients and administered in the form of indigestible tablets, buccal tablets, pastilles, pills, capsules, suspensions, potions, syrups and the like.
  • Such preparations should contain at least 0.1 % of active compound.
  • composition of the preparation may, of course, vary.
  • Preferred preparations of the pyrazole compounds of formula I according to the invention comprise from 10 to 1000 mg of active compound per oral dosage unit.
  • the tablets, pastilles, pills, capsules and the like may furthermore comprise the following components: binders, such as traganth, gum arabic, corn starch or gelatin, excipients, such as dicalcium phosphate, disintegrants, such as corn starch, potato starch, alginic acid and the like, glidants, such as magnesium stearate, sweeteners, such as sucrose, lactose or saccharin, and/or flavors, such as peppermint, vanilla and the like.
  • binders such as traganth, gum arabic, corn starch or gelatin
  • excipients such as dicalcium phosphate
  • disintegrants such as corn starch, potato starch, alginic acid and the like
  • glidants such as magnesium stearate
  • sweeteners such as sucrose, lactose or saccharin
  • flavors such as peppermint, vanilla and the like.
  • Capsules may furthermore comprise a liquid carrier.
  • tablets, pills and capsules may be coated with schellack, sugar or mixtures thereof.
  • syrups or potions may also comprise sugar (or other sweeteners), methyl- or propylparaben as preservative, a colorant and/or a flavor.
  • sugar or other sweeteners
  • methyl- or propylparaben as preservative
  • a colorant or a flavor.
  • the components of the active compound preparations must, of course, be pharmaceutically pure and nontoxic at the quantities employed.
  • the active compounds can be formulated as preparations with a controlled release of active compound, for example as delayed-release preparations.
  • the active compounds can also be administered parenterally or intraperitoneal ⁇ .
  • Solutions or suspensions of the active compounds or their salts can be prepared with water using suitable wetting agents, such as hydroxypropylcellulose.
  • Dispersions can also be prepared using glycerol, liquid polyethylene glycols and mixtures thereof in oils.
  • these preparations furthermore comprise a preservative to prevent the growth of microorganisms.
  • Preparations intended for injections comprise sterile aqueous solutions and dispersions and also sterile powders for preparing sterile solutions and dispersions.
  • the preparation has to be sufficiently liquid for injection.
  • the carrier may be a solvent or a dispersion medium, for example, water, ethanol, a polyol (for example glycerol, propylene glycol or liquid polyethylene glycol), a mixture thereof and/or a vegetable oil.
  • a solvent or a dispersion medium for example, water, ethanol, a polyol (for example glycerol, propylene glycol or liquid polyethylene glycol), a mixture thereof and/or a vegetable oil.
  • compositions of this invention suitable for parenteral administration comprise a compound of formula I in combination with one or more pharmaceutically- acceptable sterile isotonic aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable solutions or dispersions just prior to use, which may contain antioxidants, buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents.
  • aqueous and nonaqueous carriers examples include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate.
  • polyols such as glycerol, propylene glycol, polyethylene glycol, and the like
  • vegetable oils such as olive oil
  • injectable organic esters such as ethyl oleate.
  • Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
  • These compositions may also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents.
  • microorganisms Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and other antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents, such as sugars, sodium chloride, and the like into the compositions. In addition, prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents which delay absorption such as aluminum monostearate and gelatin.
  • agents which delay absorption such as aluminum monostearate and gelatin.
  • compositions of the present invention may be given by any suitable means of administration including orally, parenterally, topically, transdermal ⁇ , rectally, etc. They are of course given by forms suitable for each administration route. For example, they are administered in tablets or capsule form, by injection, inhalation, eye lotion, ointment, suppository, etc. administration by injection, infusion or inhalation; topical by lotion or ointment; and rectal by suppositories. Topical or parenteral administration is preferred.
  • Example 1 This example illustrates the preparation of 3-chloro-4-(2-chloro-4-fluoro-phenyl)- 5-(4-chloro-phenyl)-1-methyl-1 H-pyrazole (Compound No. I.e.004) a) Preparation of (E/Z)-2-(2-chloro-4-fluoro-phenyl)-3-(4-chloro-phenyl)-acrylonitrile (2-chloro-4-fluoro-phenyl)-acetonitrile (1.357g) and 4-chloro-benzaldehyde (1.125g) are dissolved in methanol (16 ml).
  • the residue is purified by chromatography on silica gel, using a mixture of heptane / ethyl acetate 4 : 5 as eluent, to deliver 0.088 g of 4-(2-chloro-4-fluoro-phenyl)-5-(4-chloro-phenyl)-1-methyl-1 H- pyrazol-3-ylamine.
  • aqueous phase is extracted twice with ethyl acetate, and the combined organic phases are dried over sodium sulfate, filtrated and evaporated under reduced pressure.
  • the residue is purified by preparative HPLC (eluant is a gradiant of ethyl acetate in hexane, stationary phase is LiChrospher Si 60 ® ), to deliver 0.008 g of 3-chloro-4-(2-chloro-4-fluoro-phenyl)-5- (4-chloro-phenyl)-1-methyl-1 H-pyrazole (Compound No.l.c.004).
  • Example 2 This example illustrates the preparation of 3-chloro-5-(4-methoxy-phenyl)-1- methyl-4-(2,4,6-trifluoro-phenyl)-1 H-pyrazole (Compound No. I. d.010)
  • the Grignard reagent produced from the 2-bromo-1 ,3,5-trifluoro-benzene is added dropwise, and the resulting reaction mixture is stirred at -55 0 C for 4 hours. Temperature is then raised to O 0 C, before addition of water (200 ml) and HCI 10% (200 ml). The aqueous layer is extracted three times with ethyl acetate, the combined organic layers are dried over sodium sulphate, filtered and concentrated under reduced pressure. 94 g of oxo-(2,4,6- trifluoro-phenyl)-acetic acid ethyl ester are then obtained, and used as such in the next step.
  • reaction mixture is stirred for 3 days at room temperature (additional 60 mg of Pd(OH) 2 and 0.7 ml of cyclohexene are added after 24 hours), before being filtered over Celite ® and concentrated under reduced pressure.
  • the residue amounts to 0.099 g of 5-chloro-3-(4- methoxy-phenyl)-4-(2, 4, 6-trifluoro-phenyl)-1 H-pyrazole, which is used as such in the next step.
  • Example 3 This example illustrates the preparation of 3-chloro-5-(4-methoxy-phenyl)-1- methyl-4-(2,6-difluoro-4-methoxy-phenyl)-1 H-pyrazole (Compound No. I.e.010)
  • the crude mixture is purified by chromatography column on silica gel, using a mixture of heptane / ethyl acetate 4:1 as eluent to obtain 0.058 g of 3-Chloro-5-(4-methoxy- phenyl)-1-methyl-4-(2,6-difluoro-4-methoxy-phenyl)-1 H-pyrazole (Compound No. I.e.010).
  • R 1 , R 2 and R 3 are as defined in Table 1.
  • Table 2 shows selected NMR data, all with CDC ⁇ as the solvent (unless otherwise stated, no attempt is made to list all characterising data in all cases) for compounds of Table 1.
  • 4-week old tomato plants cv. Roter Gnom are treated with the formulated test compound in a spray chamber.
  • the test plants are inoculated by spraying them with a spore suspension two days after application.
  • the inoculated test plants are incubated at 22/18° C (day/night) and 95% rh in a greenhouse and the percentage leaf area covered by disease is assessed when an appropriate level of disease appears on untreated check plants (5 - 7 days after application).
  • Botryotinia fuckeliana (Botrytis cinerea) I tomato / preventative (Botrvtis on tomato) 4-week old tomato plants cv. Roter Gnom are treated with the formulated test compound in a spray chamber.
  • the test plants are inoculated by spraying them with a spore suspension two days after application.
  • the inoculated test plants are incubated at 20° C and 95% rh in a greenhouse and the percentage leaf area covered by disease is assessed when an appropriate level of disease appears on untreated check plants (5 - 6 days after application).
  • Compound I.e.004 according to the invention at 200 ppm inhibits fungal infestation in this test to at least 80 %, while under the same conditions untreated control plants are infected by the phytopathogenic fungi to over 80 %.
  • Erysiphe necator Uncinula necato ⁇ I grape / preventative (Powdery mildew on grape) 5-week old grape seedlings cv. Gutedel are treated with the formulated test compound in a spray chamber.
  • the test plants are inoculated by shaking plants infected with grape powdery mildew above them 1 day after application.
  • the inoculated test plants are incubated at 24/22° C (day/night) and 70% rh under a light regime of 14/1 O h (light/dark) and the percentage leaf area covered by disease is assessed when an appropriate level of disease appears on untreated check plants (7 - 9 days after application).
  • Mycosphaerella arachidis (Cercospora arachidicola) / peanut / curative
  • 3-week old peanut plants cv. Georgia Green are inoculated by spraying them with a spore suspension on their lower leaf surface. After an incubation period of 2 days at 23° C and 100% rh, the inoculated plants are treated with the formulated test compound in a spray chamber. After an additional incubation period of 1 day under a plastic hood at 23° C and 100% rh, the test plants are kept at 23° C / 20° C (day/night) and 70% rh in a greenhouse. The percentage leaf area covered by disease is assessed when an appropriate level of disease appears on untreated check plants (10 - 12 days after application).
  • Compound I.e.004 according to the invention at 200 ppm inhibits fungal infestation in this test to at least 80 %, while under the same conditions untreated control plants are infected by the phytopathogenic fungi to over 80 %.
  • 2-week old wheat plants cv. Arina are treated with the formulated test compound in a spray chamber.
  • the test plants are inoculated by spraying them with a spore suspension one day after application. After an incubation period of 1 day at 20° C and 95% rh, the test plants are kept at 20° C / 18° C (day/night) and 60% rh in a greenhouse. The percentage leaf area covered by disease is assessed when an appropriate level of disease appears on untreated check plants (12 - 14 days after application).
  • Compound l.d.010 according to the invention at 200 ppm inhibits fungal infestation in this test to at least 80 %, while under the same conditions untreated control plants are infected by the phytopathogenic fungi to over 80 %.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Environmental Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Plant Pathology (AREA)
  • Pest Control & Pesticides (AREA)
  • Agronomy & Crop Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dentistry (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne de nouveaux dérivés de pyrazole représentés par la formule (I), ou une forme saline agrochimiquement utilisable de ces dérivés. Ces composés et sels conviennent comme principes actifs et se distinguent par leur activité microbicide et plus particulièrement fongicide. Dans la formule (I), R1 est C1-C4 alkyle ou C1-C haloalkyle; R2 est aryle ou hétéroaryle éventuellement substitué; R3 est halogène; R4 est hydrogène, halogène, C1-C4 alkyle, C1-C4 haloalkyle, cyano ou OR6; R5 est hydrogène, halogène, C1-C4 alkyle, C1-C4 haloalkyle, cyano ou OR6; R6 est hydrogène, C1-C6 alkyle, C3-C7 cycloalkyle, C3-C10 alkyle-cycloalkyle, C1-C6 haloalkyle, C2-C6 alcényle, C2-C haloalcényle, C3-C7 cycloalcényle, C2-C6 alkynyle, C2-C6 haloalkynyle, C2-C6 alkyloxyalkyle; R7 est halogène ou OR6; X est N ou C-R4.
PCT/EP2009/054386 2008-04-14 2009-04-14 Nouveaux dérivés de pyrazole Ceased WO2009127612A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP09732982A EP2274285A1 (fr) 2008-04-14 2009-04-14 Nouveaux dérivés de pyrazole

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0806744.9A GB0806744D0 (en) 2008-04-14 2008-04-14 Novel pyrazole derivatives
GB0806744.9 2008-04-14

Publications (1)

Publication Number Publication Date
WO2009127612A1 true WO2009127612A1 (fr) 2009-10-22

Family

ID=39433608

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/054386 Ceased WO2009127612A1 (fr) 2008-04-14 2009-04-14 Nouveaux dérivés de pyrazole

Country Status (4)

Country Link
EP (1) EP2274285A1 (fr)
AR (1) AR071657A1 (fr)
GB (1) GB0806744D0 (fr)
WO (1) WO2009127612A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016012424A1 (fr) 2014-07-24 2016-01-28 Bayer Cropscience Aktiengesellschaft Dérivés de pyrazole fongicide
WO2019020981A1 (fr) * 2017-07-24 2019-01-31 Redag Crop Protection Ltd. Dérivés de pyrazole, d'isothiazole et d'isoxazole utiles en tant que fongicides agricoles

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999025695A1 (fr) * 1997-11-18 1999-05-27 Fujisawa Pharmaceutical Co., Ltd. Composes 5-arylpyrazole
WO2001002385A1 (fr) * 1999-06-30 2001-01-11 Aventis Cropscience S.A. Derives de 1-(quinolin-4-yl)-1h-pyrazole et leur utilisation comme fongicides

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999025695A1 (fr) * 1997-11-18 1999-05-27 Fujisawa Pharmaceutical Co., Ltd. Composes 5-arylpyrazole
WO2001002385A1 (fr) * 1999-06-30 2001-01-11 Aventis Cropscience S.A. Derives de 1-(quinolin-4-yl)-1h-pyrazole et leur utilisation comme fongicides

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016012424A1 (fr) 2014-07-24 2016-01-28 Bayer Cropscience Aktiengesellschaft Dérivés de pyrazole fongicide
US10246420B2 (en) 2014-07-24 2019-04-02 Bayer Cropscience Aktiengesellschaft Pyrazole derivatives
WO2019020981A1 (fr) * 2017-07-24 2019-01-31 Redag Crop Protection Ltd. Dérivés de pyrazole, d'isothiazole et d'isoxazole utiles en tant que fongicides agricoles

Also Published As

Publication number Publication date
GB0806744D0 (en) 2008-05-14
AR071657A1 (es) 2010-07-07
EP2274285A1 (fr) 2011-01-19

Similar Documents

Publication Publication Date Title
EP2201000B1 (fr) Nouveaux dérivés d'imidazole
US20110224252A1 (en) Novel imidazole derivatives
US20100113464A1 (en) Novel pyridazine derivatives
US20100144674A1 (en) Pyridazine derivatives
US20100022526A1 (en) Pyridazine derivatives, processes for their preparation and their use as fungicides
EP2201001B1 (fr) Nouveaux dérivés d'imidazole
US8410026B2 (en) Pyridazine fungicides
US20100273804A1 (en) Pyridazine derivatives useful as fungicides and for the treatment of cancer
EP2279176A1 (fr) Nouveaux dérivés d'imidazole présentant une activité microbicide
EP2053044A1 (fr) Nouveaux dérivés d'imidazole
EP2274285A1 (fr) Nouveaux dérivés de pyrazole
US20120010195A1 (en) Imidazole derivatives

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09732982

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009732982

Country of ref document: EP